SAINT-PREX, Switzerland – April 9, 2025 – Ferring announced €2.3 billion in total revenues for 2024, a 7% increase year-over-year (AER) and 8% (CER), fueled by record-breaking Reproductive Medicine sales exceeding €1 billion and the first full year of U.S. sales for Adstiladrin, its gene therapy for bladder cancer. Adstiladrin (Nadofaragene firadenovec-vncg) is an FDA-approved gene therapy for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. It utilizes a non-replicating adenovirus vector to deliver a gene encoding human interferon alfa-2b, which is expressed locally in bladder cells to induce antitumor and immune-modulating effects. Administered via intravesical instillation every three months, it demonstrated a 51% complete response rate and a median response duration of 9.7 months in clinical trials. Common side effects include bladder discharge, fatigue, and urinary urgency. This therapy offers a non-surgical alternative for patients with limited treatment options.
The company achieved a 38% increase in operating profit to €192 million (AER, 43% CER) through strategic expense management and targeted investments in growth areas like Adstiladrin.
“2024 marked a year of significant progress, with strong performance in Reproductive Medicine and the emergence of Adstiladrin as a key growth driver,” stated Jean-Frédéric Paulsen, Chairman of the Board of Directors. “We are focused on maximizing our impact and delivering life-changing solutions to patients.”
https://www.ferring.com/ferring-achieved-record-sales-driven-by-reproductive-medicine-combined-with-the-emergence-of-adstiladrin/
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
